The Biotechnology Innovation Organization launched the BIO Investment Council to improve capital formation for early‑stage biotech, pairing investors and emerging companies to tackle barriers to private funding. BIO named industry leaders to chair the council and signaled the group will advise on policy and investor engagement ahead of industry events. Market signals reflected that push: private biotechs collectively pulled in roughly $2 billion in a concentrated fundraising week, with several megaround financings and venture commitments ahead of the JP Morgan conference. The twin developments underscore continuing investor interest, even as capital allocation shifts across stages.